SAUHF - Lonza: Growth Might Not Be Priced In Yet
Thesis summary
I believe that Lonza (LZAGF) is a great business that is underappreciated by the market due to its high business complexity, but strong growth should continue on the back of synergies, several global megatrends, and focus on the company's healthcare continuum. Also, the company is very likely to meet its 2022 targets.
Source: Lonza's corporate presentation
Business
Lonza Group AG is a very old Switzerland-based holding company with over 121 years of operational history. The Basel-based company is a supplier to the pharmaceutical, healthcare, and life science industries. The company's offerings include custom